Isavuconazole: a new extended spectrum triazole for invasive mold diseases.
Ananda-Rajah MR, Kontoyiannis D.
Future Microbiol · research support, non-u.s. gov't; journal article · DOI 10.2217/fmb.15.34 PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för isavuconazole. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
8 hitsIsavuconazole: A New Option for the Management of Invasive Fungal Infections.
Pettit NN, Carver PL.
Ann Pharmacother · review; journal article · DOI 10.1177/1060028015581679Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values.
Pfaller MA, Rhomberg PR, Messer SA, Jones RN, Castanheira M.
Diagn Microbiol Infect Dis · research support, non-u.s. gov't; journal article · DOI 10.1016/j.diagmicrobio.2015.04.008Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model.
Seyedmousavi S, Brüggemann RJ, Meis JF, Melchers WJ, Verweij PE, Mouton JW.
Antimicrob Agents Chemother · research support, non-u.s. gov't; research-article; journal article · DOI 10.1128/aac.04907-14Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study.
Cornely OA, Böhme A, Schmitt-Hoffmann A, Ullmann AJ.
Antimicrob Agents Chemother · clinical trial, phase ii; research support, non-u.s. gov't; research-article; multicenter study; journal article · DOI 10.1128/aac.04569-14A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasis.
Viljoen J, Azie N, Schmitt-Hoffmann AH, Ghannoum M.
Antimicrob Agents Chemother · clinical trial, phase ii; research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1128/aac.04586-14Isavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases.
Seyedmousavi S, Verweij PE, Mouton JW.
Expert Rev Anti Infect Ther · review; journal article · DOI 10.1586/14787210.2015.990382Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for the Cryptococcus neoformans-Cryptococcus gattii species complex using the CLSI M27-A3 broth microdilution method.
Espinel-Ingroff A, Chowdhary A, Gonzalez GM, Guinea J, Hagen F, Meis JF, Thompson GR, Turnidge J.
Antimicrob Agents Chemother · brief-report; multicenter study; journal article · DOI 10.1128/aac.04055-14